Kura Oncology KURA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Development Services For Monotherapy | $7.2M— | —— | —— | —— | —— | |
| Development Services In Combination With Other Therapies | $5.3M— | —— | —— | —— | —— | |
| License And Collaboration Revenue | $12.5M— | —— | —— | —— | $14.11M+4.7% | |
| Revenue Remaining Performance Obligation by Product | ||||||
| Commercialization Services | $275.7M+1.1% | $272.6M— | —— | —— | —— | |
| Development Services For Monotherapy | $27M-21.3% | $34.3M— | —— | —— | —— | |
| Development Services In Combination With Other Therapies | $161.7M-3.2% | $167M— | —— | —— | —— | |
| Research And Development Expense by Product | ||||||
| Darlifarnib | $6.57M-4.0% | $6.84M-19.4% | $8.49M+38.3% | $6.14M+17.3% | $5.24M-9.8% | |
| Discovery Stage Program | $1.4M-26.6% | $1.91M+9.3% | $1.74M+17.0% | $1.49M-28.7% | $2.09M+25.0% | |
| Ziftomenib | $36.88M+6.2% | $34.73M-13.9% | $40.32M+7.3% | $37.58M+25.5% | $29.95M+10.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
